Archived Virtual Seminar: IL-1 blockade in heart disease
Special Seminar presented by the Center for Vascular and Heart Research and the Fralin Biomedical Research Institute at VTC
IL-1 blockade in heart disease
Date: May 13, 2021
Time: 11:00 a.m. - 12:00 p.m.
About this Seminar
The intracellular sensing protein termed NLRP3 (for NACHT, LRR, and PYD domains-containing protein 3) forms a macromolecular structure called the NLRP3 inflammasome. The NLRP3 inflammasome plays a major role in inflammation, particular in the production of interleukin-1b (IL-1b). IL-1b is the most studied of the IL-1 family of cytokines, including 11 members among which IL-1a and IL-18. Dr. Abbate will summarize pre-clinical and clinical findings supporting the key pathogenetic role of the NLRP3 inflammasome and IL-1 cytokines in the formation, progression and complications of atherosclerosis, in ischemic (acute myocardial infarction, AMI), and non-ischemic injury to the myocardium (myocarditis) and the progression to heart failure (HF). He will also review the clinically available IL-1 inhibitors, although not currently approved for a cardiovascular indications, and discuss other IL-1 inhibitors, not currently approved, as well as oral NLRP3 inflammasome inhibitors currently in clinical development. Canakinumab, IL‑1b antibody, prevented the recurrence of ischemic events in patients with prior AMI in a large phase III clinical trial including 10,061 patients world-wide. Phase II clinical trials show promising data with anakinra, recombinant IL-1 receptor antagonist, in patients with ST segment elevation AMI or HF with reduced ejection fraction. Anakinra also improved outcomes in patients with pericarditis and it is now considered standard of care as second line treatment for patients with recurrent/refractory pericarditis. Rilonacept, a soluble IL‑1 receptor chimeric fusion protein neutralizing IL-1aand IL-1b, has also shown promising results in a phase II study in recurrent/ refractory pericarditis. In conclusion, there is overwhelming evidence linking the NLRP3 inflammasome and the IL-1 cytokines with the pathogenesis of cardiovascular diseases. The future will likely include targeted inhibitors to block the IL‑1 isoforms, and possibly oral NLRP3 inflammasome inhibitors, across a wide spectrum of cardiovascular diseases.
You May Also Be Interested In...
Home ItemIn Person Seminar: Win to Fight and Lose to Flight: Innate Yet Flexible Aggression Circuit , home
March 24, 2023, 11 a.m. | Dayu Lin, Ph.D., Professor, Department of Psychiatry, Grossman School of Medicine, New York University | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Neurobiology Research
Home ItemSeminar: Signaling and Metabolic Control of Nucleotide Metabolism in Cancer , home
March 27, 2023, 11 a.m. | Eunus S. Ali, Ph.D., Postdoctoral Associate, Department of Biochemistry and Molecular Genetics, Feinberg School of Medicine, Northwestern University | Seminar
Home ItemIn Person Seminar: Quantifying Diverse Research Representation , home
March 31, 2023, 11:00 a.m. | Jonathan Jackson, Ph.D., Executive Director, Community Access, Recruitment, and Engagement (CARE) Research Center, Harvard University and Massachusetts General Hospital | Pioneers in Biomedical Research Seminar Series | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
Home ItemIn Person Lecture: Synaptic Injury: A Link to the Past , home
March 31, 2023, 1 p.m. | Terrance Kummer, M.D., Ph.D., Associate Professor of Neurology, Washington University School of Medicine in St. Louis | Timothy A. Johnson Medical Scholar Lecture Series
Home ItemSeminar: Understanding Cancer: From Development to Therapy , home
April 5, 2023, 11 a.m. | Biplab Dasgupta, M.S., Ph.D., MBA, Professor of Pediatrics, Division of Oncology, Cincinnati Children's Hospital | Seminar
Antonio Abbate, M.D., Ph.D.
James C. Roberts, Esq., Professor of Cardiology, Department of Internal Medicine, Division of Cardiology, VCU Pauley Heart Center; and Professor, Department of Internal Medicine and Department of Physiology and Biophysics, Virginia Commonwealth University